EA008585B1 - Капсулы флуконазола с улучшенным высвобождением - Google Patents
Капсулы флуконазола с улучшенным высвобождением Download PDFInfo
- Publication number
- EA008585B1 EA008585B1 EA200600085A EA200600085A EA008585B1 EA 008585 B1 EA008585 B1 EA 008585B1 EA 200600085 A EA200600085 A EA 200600085A EA 200600085 A EA200600085 A EA 200600085A EA 008585 B1 EA008585 B1 EA 008585B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- capsules
- fluconazole
- weight
- particles
- possibly
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 110
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 229960004884 fluconazole Drugs 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 239000002245 particle Substances 0.000 claims abstract description 60
- 239000004480 active ingredient Substances 0.000 claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 230000005660 hydrophilic surface Effects 0.000 claims abstract description 14
- 238000005469 granulation Methods 0.000 claims abstract description 10
- 230000003179 granulation Effects 0.000 claims abstract description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 30
- 239000004094 surface-active agent Substances 0.000 claims description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 23
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
- 239000008101 lactose Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- 239000000314 lubricant Substances 0.000 claims description 17
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 17
- 239000007884 disintegrant Substances 0.000 claims description 16
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000945 filler Substances 0.000 claims description 15
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229920000881 Modified starch Polymers 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000000346 sugar Nutrition 0.000 claims description 8
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000001913 cellulose Chemical class 0.000 claims description 4
- 229920002678 cellulose Chemical class 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical group 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011256 inorganic filler Substances 0.000 claims 4
- 229910003475 inorganic filler Inorganic materials 0.000 claims 4
- 239000012766 organic filler Substances 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 150000001342 alkaline earth metals Chemical group 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical group [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 49
- 238000010521 absorption reaction Methods 0.000 abstract description 21
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 description 17
- 229960001375 lactose Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 229960001021 lactose monohydrate Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012752 auxiliary agent Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0302030A HU227142B1 (en) | 2003-07-02 | 2003-07-02 | Capsule of improved release containing fluconazole |
| PCT/HU2004/000071 WO2005002553A2 (en) | 2003-07-02 | 2004-06-30 | Fluconazole capsules with improved release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200600085A1 EA200600085A1 (ru) | 2006-08-25 |
| EA008585B1 true EA008585B1 (ru) | 2007-06-29 |
Family
ID=89981480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600085A EA008585B1 (ru) | 2003-07-02 | 2004-06-30 | Капсулы флуконазола с улучшенным высвобождением |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1648451A2 (cs) |
| CN (1) | CN1812783A (cs) |
| BG (1) | BG109430A (cs) |
| CZ (1) | CZ200657A3 (cs) |
| EA (1) | EA008585B1 (cs) |
| HU (1) | HU227142B1 (cs) |
| PL (1) | PL380995A1 (cs) |
| SK (1) | SK50132006A3 (cs) |
| UA (1) | UA82532C2 (cs) |
| WO (1) | WO2005002553A2 (cs) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3971C2 (ro) * | 2009-04-29 | 2010-06-30 | Дмитрий СКУРТУ | Scaun-trenajor |
| RU2535037C2 (ru) * | 2009-01-19 | 2014-12-10 | Нейтресин Юк Лимитед | Комбинация фульвовой кислоты для лечения различных состояний и болезней |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DK2736495T3 (da) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel |
| BR112014001091A2 (pt) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | comprimido resistente à adulteração que fornece liberação imediata do fármaco |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| CN105616378A (zh) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | 一种氟康唑胶囊及其制备方法 |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| CN113230236A (zh) * | 2021-04-29 | 2021-08-10 | 山东优杰生物科技有限公司 | 祛除灰指甲草本贴及其制备方法 |
| CN117137878A (zh) * | 2023-07-16 | 2023-12-01 | 海南林恒制药股份有限公司 | 一种氟康唑胶囊及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018757A1 (en) * | 1992-03-17 | 1993-09-30 | Pfizer Inc. | Method of producing porous delivery devices |
| WO2000056726A1 (en) * | 1999-03-24 | 2000-09-28 | Fmc Corporation | Improved aqueous solubility pharmaceutical formulations |
| US6214386B1 (en) * | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
| WO2001041765A1 (en) * | 1999-12-08 | 2001-06-14 | Dong A Pharm. Co., Ltd. | Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| RU2201230C1 (ru) * | 2001-12-24 | 2003-03-27 | Закрытое акционерное общество "Брынцалов-А" | Лекарственное средство флузол, обладающее противогрибковым действием |
-
2003
- 2003-07-02 HU HU0302030A patent/HU227142B1/hu not_active IP Right Cessation
-
2004
- 2004-06-30 CN CNA2004800184777A patent/CN1812783A/zh active Pending
- 2004-06-30 PL PL380995A patent/PL380995A1/pl not_active IP Right Cessation
- 2004-06-30 SK SK5013-2006A patent/SK50132006A3/sk not_active Application Discontinuation
- 2004-06-30 WO PCT/HU2004/000071 patent/WO2005002553A2/en not_active Ceased
- 2004-06-30 CZ CZ20060057A patent/CZ200657A3/cs unknown
- 2004-06-30 EA EA200600085A patent/EA008585B1/ru not_active IP Right Cessation
- 2004-06-30 EP EP04743730A patent/EP1648451A2/en not_active Withdrawn
- 2004-06-30 UA UAA200600919A patent/UA82532C2/uk unknown
-
2006
- 2006-02-02 BG BG109430A patent/BG109430A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018757A1 (en) * | 1992-03-17 | 1993-09-30 | Pfizer Inc. | Method of producing porous delivery devices |
| US6214386B1 (en) * | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
| WO2000056726A1 (en) * | 1999-03-24 | 2000-09-28 | Fmc Corporation | Improved aqueous solubility pharmaceutical formulations |
| WO2001041765A1 (en) * | 1999-12-08 | 2001-06-14 | Dong A Pharm. Co., Ltd. | Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| RU2201230C1 (ru) * | 2001-12-24 | 2003-03-27 | Закрытое акционерное общество "Брынцалов-А" | Лекарственное средство флузол, обладающее противогрибковым действием |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI, Section Ch, Week 200347, Derwent Publications Ltd., London, GB; Class B05, AN 2003-502496, XP002314064 & RU 2201230 C1 (BRYNTSALOV A STOCK CO), 27 March, 2003 (2003-03-27), abstract * |
| EL-ASSASY A I ET AL: "Factorial design-based formulation of fluconazol capsules" EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 39, no. 4-6, 1998, pages 337-346, XP009042805 ISSN: 0301-5068 * |
| PORTA V. ET AL.: "Evaluation of the bioequivalence of capsules containing 150 mg of fluconazole", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 288, no. 1, 6 January, 2005 (2005-01-06), pages 81-86, XP004682403, ISSN: 0378-5173, the whole document * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2535037C2 (ru) * | 2009-01-19 | 2014-12-10 | Нейтресин Юк Лимитед | Комбинация фульвовой кислоты для лечения различных состояний и болезней |
| MD3971C2 (ro) * | 2009-04-29 | 2010-06-30 | Дмитрий СКУРТУ | Scaun-trenajor |
Also Published As
| Publication number | Publication date |
|---|---|
| SK50132006A3 (sk) | 2006-05-04 |
| CZ200657A3 (cs) | 2006-04-12 |
| HUP0302030A2 (hu) | 2005-03-29 |
| PL380995A1 (pl) | 2007-04-16 |
| WO2005002553A3 (en) | 2005-03-24 |
| BG109430A (en) | 2006-11-30 |
| EA200600085A1 (ru) | 2006-08-25 |
| UA82532C2 (uk) | 2008-04-25 |
| CN1812783A (zh) | 2006-08-02 |
| HU227142B1 (en) | 2010-08-30 |
| EP1648451A2 (en) | 2006-04-26 |
| WO2005002553A2 (en) | 2005-01-13 |
| HU0302030D0 (en) | 2003-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7627302B2 (ja) | パルボシクリブの固形剤形 | |
| RU2311903C2 (ru) | Таблетки тамзулосина | |
| EP2331074B1 (en) | Granulates, process for preparing them and pharmaceutical products containing them | |
| DE69905380T2 (de) | Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen | |
| JP6396980B2 (ja) | ベンダムスチンの固体投与剤 | |
| US6531158B1 (en) | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients | |
| US6656929B1 (en) | Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process | |
| EA004872B1 (ru) | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| EP3437646A1 (en) | Oral preparation having exceptional elutability | |
| SK14612000A3 (sk) | Príprava rýchlorozpustných efavirenzových kapsúl alebo tabliet použitím superčinidiel podporujúcich rozpadavosť | |
| US20100204292A1 (en) | Pharmaceutical compositions comprising intra-and extra-granular fractions | |
| KR20100015764A (ko) | 프레가발린을 포함하는 안정한 약학적 조성물 | |
| HU228825B1 (en) | Glyburide composition | |
| EA008585B1 (ru) | Капсулы флуконазола с улучшенным высвобождением | |
| US20100034885A1 (en) | Formulations containing glimepiride and/or its salts | |
| JP2024528260A (ja) | 難溶性薬物の浸透圧ポンプ制御放出錠剤及びその製造方法 | |
| CZ20012553A3 (cs) | Farmaceutická směs obsahující kombinaci profenu a jiných účinných látek | |
| WO2007069274A2 (en) | Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent | |
| JP2002532538A (ja) | プロフェンを含有する医薬混合物 | |
| WO1999020277A1 (en) | Rapidly soluble drug composition | |
| WO2025166343A1 (en) | Tablet formulation of tafamidis or pharmaceutically acceptable salt thereof | |
| CN100420437C (zh) | 磷酸川芎嗪缓释微丸及制备方法 | |
| EP3928771A1 (en) | Pharmaceutical compositions of 1,2-benzisoxazole-3-methanesulfonamide | |
| US20250248977A1 (en) | Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof | |
| WO2024225996A1 (en) | A new pharmaceutical tablet composition comprising eltrombopag olamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |